Clinical trial
A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes
NCT05168202 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 19, 2022
- Completion date
- July 30, 2024
- Enrollment
- 56 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.